CA3066738A1 - Methodes et compositions pour le traitement du cancer - Google Patents

Methodes et compositions pour le traitement du cancer

Info

Publication number
CA3066738A1
CA3066738A1 CA3066738A CA3066738A CA3066738A1 CA 3066738 A1 CA3066738 A1 CA 3066738A1 CA 3066738 A CA3066738 A CA 3066738A CA 3066738 A CA3066738 A CA 3066738A CA 3066738 A1 CA3066738 A1 CA 3066738A1
Authority
CA
Canada
Prior art keywords
elane
composition
polypeptide
cancer
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3066738A
Other languages
English (en)
Inventor
Lev BECKER
Chang CUI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Chicago
Original Assignee
Becker Lev
Cui Chang
University of Chicago
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Becker Lev, Cui Chang, University of Chicago filed Critical Becker Lev
Publication of CA3066738A1 publication Critical patent/CA3066738A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/54—Mixtures of enzymes or proenzymes covered by more than a single one of groups A61K38/44 - A61K38/46 or A61K38/51 - A61K38/53
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/26—Endoribonucleases producing 5'-phosphomonoesters (3.1.26)
    • C12Y301/26003—Ribonuclease III (3.1.26.3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21037—Leukocyte elastase (3.4.21.37), i.e. neutrophil-elastase

Abstract

Des modes de réalisation concernent : (i) des facteurs sécrétés par les neutrophiles qui ont la capacité de détruire une large gamme de cellules cancéreuses sans affecter la viabilité des cellules non cancéreuses. Deux facteurs de destruction des neutrophiles ont été identifiés par les inventeurs : (1) la protéine cationique de l'éosinophile (ECP) et (2) l'élastase du polynucléaire neutrophile (ELANE); ou (ii) des compositions thérapeutiques qui comprennent des composants polypeptidiques dégradant le CD95, et des méthodes de traitement du cancer avec ces dernières.
CA3066738A 2017-06-15 2018-06-15 Methodes et compositions pour le traitement du cancer Pending CA3066738A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762520325P 2017-06-15 2017-06-15
US62/520,325 2017-06-15
US201762610711P 2017-12-27 2017-12-27
US62/610,711 2017-12-27
PCT/US2018/037800 WO2018232273A1 (fr) 2017-06-15 2018-06-15 Méthodes et compositions pour le traitement du cancer

Publications (1)

Publication Number Publication Date
CA3066738A1 true CA3066738A1 (fr) 2018-12-20

Family

ID=64659547

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3066738A Pending CA3066738A1 (fr) 2017-06-15 2018-06-15 Methodes et compositions pour le traitement du cancer

Country Status (9)

Country Link
US (1) US20210299234A1 (fr)
EP (2) EP4292606A3 (fr)
JP (2) JP7189160B2 (fr)
CN (1) CN111032075A (fr)
AU (1) AU2018285710A1 (fr)
CA (1) CA3066738A1 (fr)
DK (1) DK3638293T3 (fr)
ES (1) ES2962985T3 (fr)
WO (1) WO2018232273A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019403393A1 (en) * 2018-12-20 2021-08-05 The University Of Chicago Methods and compositions related to therapeutic peptides for cancer therapy
CN112812150A (zh) * 2021-01-29 2021-05-18 深圳海创生物科技有限公司 一种活性环肽、活性环肽组合物及其在制备具有抗氧化或抗炎作用的产品中的应用
CN113736742B (zh) * 2021-09-08 2023-07-21 河南省医药科学研究院 Prtn3基因作为肿瘤免疫治疗中激活细胞毒性免疫细胞靶点的应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3941763A (en) 1975-03-28 1976-03-02 American Home Products Corporation PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
CA2087730C (fr) * 1990-08-03 1999-07-20 Manuel A. Navia Utilisation de cristaux reticules, nouvelle forme d'immobilisation des enzymes
US5698518A (en) * 1994-03-30 1997-12-16 Oklahoma Medical Research Foundation Method for regulating inflammation and tumor growth with calmodulin, calmodulin analogues or calmodulin antagonists
CA2500405A1 (fr) 2002-09-30 2004-04-15 Oncotherapy Science, Inc. Genes et polypeptides se rapportant a la leucemie myeloide humaine
JP4408615B2 (ja) 2002-10-07 2010-02-03 独立行政法人科学技術振興機構 好酸球カチオン性タンパク質を含有する組成物
US8068990B2 (en) * 2003-03-25 2011-11-29 Hologic, Inc. Diagnosis of intra-uterine infection by proteomic analysis of cervical-vaginal fluids
EP1639090A4 (fr) * 2003-06-09 2008-04-16 Univ Michigan Compositions et methodes de traitement et de diagnostic du cancer
EP1649289B1 (fr) * 2003-07-21 2008-10-22 Roche Diagnostics GmbH Utilisation de la proteinase 3(prn3) et de l'inhibiteur de l'elastase leucocytaire (ileu) en tant que marqueur pour le cancer colorectal
US7432419B2 (en) * 2004-05-14 2008-10-07 Los Alamos National Security, Llc Compositions and methods for the treatment of Pierce's disease
US20060008891A1 (en) * 2004-06-23 2006-01-12 The Government Of Usa As Repersented By The Secretary, Department Of Health And Human Services Cathepsin G-related peptides as modulators of formylpeptide receptors (FPR)
CA2731216A1 (fr) * 2008-07-18 2010-01-21 Oragenics, Inc. Compositions pour la detection et le traitement du cancer colorectal
GB201121070D0 (en) 2011-12-07 2012-01-18 Isis Innovation composition for delivery of biotherapeutics
WO2016125330A1 (fr) * 2015-02-02 2016-08-11 原　英彰 Médicament favorisant la régénération rétinienne

Also Published As

Publication number Publication date
ES2962985T3 (es) 2024-03-22
WO2018232273A1 (fr) 2018-12-20
EP3638293A4 (fr) 2021-03-10
EP4292606A2 (fr) 2023-12-20
CN111032075A (zh) 2020-04-17
JP2020524141A (ja) 2020-08-13
AU2018285710A1 (en) 2020-01-23
EP4292606A3 (fr) 2024-02-21
EP3638293A1 (fr) 2020-04-22
DK3638293T3 (da) 2023-11-06
EP3638293B1 (fr) 2023-10-04
US20210299234A1 (en) 2021-09-30
JP7189160B2 (ja) 2022-12-13
JP2023022242A (ja) 2023-02-14

Similar Documents

Publication Publication Date Title
JP2023022242A (ja) がんを処置するための方法および組成物
EP2234642B1 (fr) Méthode propre à accroître un effet immunologique
US20230201305A9 (en) Immune checkpoint inhibitor combinations
EP3197493B1 (fr) Procédés d'inversion de la cachexie et de prolongation de la survie, comprenant l'administration d'un modulateur de gdf15 et d'un agent anticancéreux
WO2021012886A1 (fr) Composition pharmaceutique combinée antinéoplasique et son application
US11081235B2 (en) Extracellular matrix metalloproteinase inducer (EMMPRIN) peptides and binding antibodies
WO2019213686A1 (fr) Compositions thérapeutiques et leurs utilisations
US20220000977A1 (en) Methods and compositions related to therapeutic peptides for cancer therapy
Orsolic Possible molecular targets of bee venom in the treatment of cancer: application and perspectives
WO2018088933A1 (fr) Effets anti-tumoraux d'un vecteur viral codant pour un récepteur de type toll et un agoniste de récepteur de type toll
WO2017042318A1 (fr) Polypeptide de chémérine pour le traitement de la cachexie provoquée par le cancer
Wagner Investigation of a novel small molecule TRAIL inducer, ONC201: pre-clinical anti-cancer efficacy, anti-metastasis effects, tumor immunity; and the structure-activity relationships (SAR) and mechanism of action of potential analogues
US20150258194A1 (en) Modulating transendothelial migration and recruitment of granulocytes by modulating c-met pathway
O’Reilly12 et al. Platelets induce apoptosis via membrane-bound FasL
Pan et al. 105: The role of CD40 in the development of tumor-specific T regulatory cells and its potential use in immune therapy for cancer

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20230615